Serum Helicobacter pylori CagA antibody may not be used as a tumor marker for diagnosing gastric cancer in east Asian countries

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12217-12224

  Zhao, Zhicheng ^a   Li, Yuhong ^b   Liu, Shengxin ^c   Fu, Weihua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Liao Cheng University   (China)

^c ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Anti CagA antibody; Diagnosis; East Asia; Gastric cancer; Meta analysis

Indexed keywords

BACTERIUM ANTIBODY; CAGA PROTEIN; TUMOR MARKER; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CAGA PROTEIN, HELICOBACTER PYLORI;

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CHINA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EAST ASIAN; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HELICOBACTER PYLORI; HUMAN; IMMUNOBLOTTING; JAPAN; KOREA; META ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SYSTEMATIC REVIEW; BLOOD; DIAGNOSTIC USE; FAR EAST; HELICOBACTER INFECTION; IMMUNOLOGY; REPRODUCIBILITY; RISK; STOMACH NEOPLASMS;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FAR EAST; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ODDS RATIO; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925286615     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2530-8     Document Type: Article

References (33)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.
3. National Comprehensive Cancer Network (2010) Clinical practice guidelines in oncology: gastric cancer. http://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf. Accessed 14 August 2010.
4. Jeung HC, Rha SY, Noh SH, et al. Adjuvant 5-fluorouracil plus doxorubicin in D2–3 resected gastric carcinoma: 15-year experience at a single institute. Cancer. 2001;91(11):2016–25.
5. Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14(1):243–50.
6. Society AAC. Global cancer facts & figures 2nd edition. American Cancer: Society; 2011.
7. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113–29.
8. Garcia M, Jemal A. Global cancer facts and figures 2011. Atlanta, GA: American Cancer Society; 2011.
9. Tan YK, Fielding JW. Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol. 2006;18:821–9.
10. Blaser M, Perez-Perez G, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing CagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55(10):2111–5.
11. Kuipers E, Pérez-Pérez G, Meuwissen S, Blaser M. Helicobacter pylori and atrophic gastritis: importance of the CagA status. J Natl Cancer Inst. 1995;87(23):1777–80.
12. Nomura A, Lee J, Stemmermann G, Nomura R, Perez-Perez G, Blaser M. Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis. 2002;186(8):1138–44.
13. Parsonnet J, Friedman G, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;40(3):297–301.
14. Argent R, Hale J, El-Omar E, Atherton J. Differences in Helicobacter pylori CagA tyrosine phosphorylation motif patterns between western and east Asian strains, and influences on interleukin-8 secretion. J Med Microbiol. 2008;57(9):1062–7.
15. Huang J, Zheng G, Sumanac K, Irvine E, Hunt R. Meta-analysis of the relationship between CagA seropositivity and gastric cancer. Gastroenterology. 2003;125(6):1636–44.
16. Shiota S, Matsunari O, Watada M, Yamaoka Y. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol. 2010;5(12):1885–93.
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.
18. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9.
19. Mitchell H, Hazell S, Li Y, Hu P. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol. 1996;91(9):1785–8.
20. Shimoyama T, Fukuda S, Tanaka M, Mikami T, Munakata A, Crabtree J. CagA seropositivity associated with development of gastric cancer in a Japanese population. J Clin Pathol. 1998;51(3):225–8.
21. Kikuchi S, Crabtree J, Forman D, Kurosawa M. Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research group on prevention of gastric carcinoma among young adults. Am J Gastroenterol. 1999;94(12):3455–9.
22. Maeda S, Yoshida H, Ogura K, et al. Assessment of gastric carcinoma risk associated with Helicobacter pylori may vary depending on the antigen used: CagA specific enzyme-linked immunoadsorbent assay (ELISA) versus commercially available H. pylori ELISAs. Cancer. 2000;88(7):1530–5.
23. Ying W, Zhiquan Z, Hongjie Z, Xiaoyong Z, Lin L. CagA-positive H. pylori serology infection and its clinical significance. Jiangsu Med J. 2000;26(7):541–2. in Chinese.
24. Jianyi W, Daozeng G, Guangrong R. Relationship serology and CagA-positive H. pylori infection and gastrointestinal diseases. ACTA ACADEMIAE MEDICINAE SUZHOU. 2000;20(11):1056–8. in Chinese.
25. Limburg P, Qiao Y, Mark S, et al. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian. China J Natl Cancer Inst. 2001;93(3):226–33.
26. Sasazuki S, Inoue M, Iwasaki M, et al. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case–control study. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1341–7.
27. Gwack J, Shin A, Kim C, et al. CagA-producing Helicobacter pylori and increased risk of gastric cancer: a nested case–control study in Korea. Br J Cancer. 2006;95(5):639–41.
28. Xiao-hui CHEN, Xiu-xia LEI, Bang-lao XU. Correlation between CagA Antibody against Helicobacter pylori and the gastroduodenal diseases. J Trop Med Parasitol. 2006;6(2):167–9 (in Chinese).
29. Jin-de HE, Yu-lan LIU, Huai-tang WANG, Hui YE, Jiao ZHANG. Relationship between CagA seropositivity of Helicobacter pylori and gastrointestinal malignant tumor. Journal of Chinese Physician. 2006;8(5):617–9 (in Chinese).
30. Suzuki G, Cullings H, Fujiwara S, et al. Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1224–8.
31. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129–35.
32. Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79:16–20.
33. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237–56.